Journal of Asthma and Allergy (Oct 2019)
Characterizing Real-World Use Of Tiotropium In Asthma In The USA
Abstract
Carlyne M Averell,1 François Laliberté,2 Mei Sheng Duh,3 Jennifer W Wu,2 Guillaume Germain,2 Sarai Faison4 1US Value Evidence and Outcomes, GlaxoSmithKline, Research Triangle Park, NC, USA; 2Groupe d’analyse, Ltée, Montreal, QC, Canada; 3Analysis Group, Inc, Boston, MA, USA; 4US Medical Affairs, GlaxoSmithKline, Research Triangle Park, NC, USACorrespondence: Carlyne M AverellUS Value Evidence and Outcomes, GlaxoSmithKline, 5 Moore Drive, PO Box 13398, Research Triangle Park, NC 27709-3398, USATel +1 919 315 9835Email [email protected]: Tiotropium bromide (TIO) is a long-acting muscarinic antagonist recommended as an add-on therapy option for patients with uncontrolled asthma on inhaled corticosteroids (ICS) and long-acting β2-agonists (LABA). However, real-world data on TIO use in asthma remains limited. To identify unmet needs, this study explored the use of TIO in US patients with asthma.Methods: This retrospective cohort study used IQVIATM Health Plan Claims Data (October 1, 2014─December 31, 2016). Patients with asthma diagnoses initiating TIO 1.25 or 2.5 mcg after September 16, 2015 (first dispensing on index date) with ≥6 and ≥3 months continuous enrollment pre- and post-index, respectively, were identified. Patients with COPD diagnoses were excluded. Baseline characteristics, healthcare resource utilization and costs, and treatment patterns before and following TIO initiation were described for TIO cohorts and subgroups classified by concomitant medications received during the 30-day period after initiation.Results: The study included 766 TIO 1.25 mcg and 1055 TIO 2.5 mcg users. In the TIO 1.25 mcg cohort, 16% (126/766) used TIO monotherapy while 61% (465/766) used TIO+ICS/LABA± leukotriene receptor antagonists (triple therapy). In TIO 1.25 mcg monotherapy and triple therapy subgroups, 39% and 49% were treated by allergists/pulmonologists, 27% and 48% experienced a moderate/severe asthma exacerbation, and 50% and 68% used rescue oral corticosteroids during the baseline period, respectively. Following triple therapy initiation, 44% of patients discontinued ICS within 6 months. The TIO 2.5 mcg cohort demonstrated similar trends.Conclusion: This study provided insights into real-world US use of TIO in asthma. Overall, 16–19% of patients received TIO monotherapy and had high baseline exacerbation rates, suggesting that additional ICS-containing medication may be beneficial. Patients initiating triple therapy were among the most severe, with high baseline exacerbation rates and rescue medication use, and had high post-treatment ICS discontinuation rates, suggesting unmet needs in this population.Keywords: LAMA, tiotropium, asthma, treatment patterns, triple therapy
